Compare · ABT vs BIOA
ABT vs BIOA
Side-by-side comparison of Abbott Laboratories (ABT) and BioAge Labs Inc. (BIOA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and BIOA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $221.65B.
- Over the past year, ABT is down 29.7% and BIOA is up 289.7% - BIOA leads by 319.4 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 5 for BIOA).
- ABT has more recent analyst coverage (25 ratings vs 13 for BIOA).
- Company
- Abbott Laboratories
- BioAge Labs Inc.
- Price
- $91.15-1.41%
- $17.03-1.25%
- Market cap
- $221.65B
- -
- 1M return
- -13.05%
- +3.94%
- 1Y return
- -29.66%
- +289.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 13
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- SEC Form S-8 filed by Abbott Laboratories
- Abbott Labs downgraded by Daiwa Securities with a new price target
- Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
- SEC Form 4 filed by Stratton John G
- SEC Form 4 filed by Roman Michael F
Latest BIOA
- Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)
- SEC Form DEFA14A filed by BioAge Labs Inc.
- SEC Form DEF 14A filed by BioAge Labs Inc.
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
- BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Rubin Paul D
- SEC Form 144 filed by BioAge Labs Inc.
- Needham initiated coverage on BioAge Labs with a new price target
- SEC Form S-3ASR filed by BioAge Labs Inc.
- SEC Form S-8 filed by BioAge Labs Inc.